Glatiramer acetate in multiple sclerosis: A review

CNS Drug Reviews

Volumn 13, Issue 2, 2007, Pages 178-191

  Ruggieri, Maddalena ^a   Avolio, Carlo ^b   Livrea, Paolo ^a   Trojano, Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Antiinflammatory drugs; EAE; Experimental allergic encephalomyelitis; Glatiramer acetate; Multiple sclerosis; Neuroprotection

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTEROID; ESTRIOL; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINOCYCLINE; N ACETYLASPARTIC ACID; TV 3606; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALITIS; ANXIETY; APOPTOSIS; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEST TIGHTNESS; CLINICAL TRIAL; DISABILITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; FLUSHING; HEART PALPITATION; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; MONOTHERAPY; MULTIPLE SCLEROSIS; NERVE INJURY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; PATHOGENESIS; PROTEIN EXPRESSION; RELAPSE; REMISSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; AMINO ACIDS; HUMANS; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; PEPTIDES; POLYMERS;

EID: 34447299372     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2007.00010.x     Document Type: Review

References (70)

1. Aharoni R, Eilam R, Domey H, Labunskay G, Sela M, Arnon R (2005) The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental allergic encephalomyelitis mice. Proc Natl Acad Sci USA 102 : 19045 19050.
2. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R (2003) Glatiramer acetate-specific T cells in the brain express 2/3 cytokines and brain derived neurotrophic factor in situ. Proc Natl Acad Sci USA 100 : 14157 14162.
3. Aharoni R, Schlegel PG, Teitelbaum D, Roikhel-Karpov O, Chen Y, Arnon R, Sela M, Chao NJ (1997a) Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. Immunol Lett 58 : 79 87.
4. Aharoni R, Teitelbaum D, Sela M, Arnon R (1997b) Copolymer 1 induces T cells of the T helper type 2 that cross-react with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 94 : 10821 10826.
5. Aharoni R, Teitelbaum D, Sela M, Arnon R (1998) Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 91 : 135 146.
6. Aharoni R., Teitelbaum D, Arnon R, Sela M (1999) Copolymer 1 acts against the immunodominant epitome 82-100 of myelin basic protein by T cell receptor antagonism in additino to major histocompatibility complex blocking. Proc Natl Acad Sci USA 96 : 634 639.
7. Aharoni R., Teitelbaum D, Leitner O, Meshorer A, Sela M, Arnon R (2000) Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci USA 97 : 11472 11477.
8. Aktas O, Ari N, Rieks M, Hoffmann V, Schimrigk S, Przuntek H, Pohlau D (2001) Multiple sclerosis modulation of apoptosis susceptibility by glatiramer acetate. Acta Neurol Scand 104 : 266 270.
9. Ben-Nun A, Mendel I, Bakimer R, Fridkis-Hareli M, Teitelbaum D, Arnon R, Sela M, Kerlero de Rosbo N (1996) The autoimmune reactivity to myelin oligodendrocyte glycoprotein [MOG] in multiple sclerosis is potentially pathogenic: Effect of copolymer-1 on MOG-induced disease. J Neurol 243 : S14 S22.
10. Boneschi FM, Rovaris M, Johnson KP (2003) Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: Meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 9 : 349 355.
11. Bornstein MB, Miller A, Slagle S (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317 : 408 414.
12. Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, River-Kreitman R, Tarcik N, Teitelbaum D (2001) Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 115 : 152 160.
13. Chen M, Dhib-Jalbut S (2003) Glatiramer acetate (GA)-reactive T-cells produce brain-derived neurotrophic factor (BDNF). J Neurol Sci 215 : 37 44.
14. Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S (2001) Glatiramer acetate induces a Th2-biased response and cross reactivity with myelin basic protein in patients with MS. Mult Scler 7 : 209 219.
15. Cohen J, Rovaris M, Goodman A, Filippi M The MRI-AC Study Group (2006) Results of a randomized, double-blind, parallel-group study assessing safety and efficacy of 40 mg versus 20 mg of glatiramer acetate on MRI-measured disease activity in RRMS. Neurology 66 : S61.
16. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49 : 290 297.
17. Compston A, Coles A (2000) Multiple sclerosis. Lancet 359 : 1221 1231.
18. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, Antel JP, Arnold DL (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121 : 1469 1477.
19. Dhib-Jalbut S (2002) Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58 : S3 S9.
20. Dressel A, Vogelgesang A, Brinkmeier H, Mader M, Weber F (2006) Glatiramer acetate-specific human CD8+ T cells: Increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment. J Neuroimmunol 181 : 133 140.
21. Duda PW, Krieger JI, Schmied MC, Balentine C, Hafler DA (2000a) Human and murine CD4 T cell reactivity to a complex antigen: Recognition of the synthetic random polypeptide glatiramer acetate. J Immunol 165 : 7300 7307.
22. Duda PW, Schmied MC, Cook SL (2000b) Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105 : 967 976.
23. Farina C, Then Berg F, Albrecht H, Meinl E, Yassouridis A, Neuhaus O, Hohlfeld R (2001) Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-γ response in blood cells. Brain 124 : 705 719.
24. Filippi M, Wolinsky JS, Comi G The CORAL Study Group (2006) Effect of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, double-blind, randomized, placebo-controlled study. Lancet Neurol 5 : 213 220.
25. Ford CC, KP Johnson, RP Lisak, HS Panitch, G Shifroni, JS Wolinsky The Copaxone Study Group (2006) A prospective open-label study of glatiramer acetate: Over a decade of continuous use in multiple sclerosis patients. Mult Scler 12 : 309 320.
26. Fridkis-Hareli M, Teitelbaum D, Pecht I, Arnon R, Sela M (1997). Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells. Int Immunol 9 : 925 934.
27. Gilgun-Sherki Y, Panet H, Holdengrgber V, Mosberg-Galili R, Offen D (2003) Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res 47 : 201 207.
28. Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, Martin R (2000) Mechanisms of immunomodulation by glatiramer acetate. Neurology 55 : 1704 1714.
29. Hafler DA (2002) Degeneracy, as opposed to specificity, in immunotherapy. J Clin Invest 109 : 581 584.
30. Hohlfeld R (1999) Therapeutic strategies in multiple sclerosis: Immunotherapy. Philos Trans R Soc Lond B Biol Sci 354 : 1697 1710.
31. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50 : 701 708.
32. Johnson KP, Brooks BR, Cohen JA (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of phase III multicenter, double blind, placebo-controlled trial. Neurology 45 : 1268 1276.
33. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP (2000) Sustained clinical benefits of glatiramer acetate in relapsing remitting multiple sclerosis patients observed for 6 years. Mult Scler 6 : 255 266.
34. Johnson KP, Brooks BR, Ford CC, Goodman A, Lisak RP, Meyers LW, Pruitt AA, Rizzo MA, Rose JW, Weiner LP, et al 2003) Glatiramer acetate (Copaxone): Comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler 9 : 585 591.
35. Johnson KP, Ford CC, Lisak RP, Wolinsky JS (2005) Glatiramer acetate (Copaxone): Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 111 : 42 47.
36. Khan OA, Shen Y, Caon C (2005) Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 6 : 646 651.
37. Keith AB, Arnon R, Teitelbaum D, Caspary EA, Wisniewski HM (1979) The effect of Cop 1, a synthetic polypeptide on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci 42 : 267 274.
38. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M, Cohen IR, Schwartz M (2000) T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neuropathies. Proc Natl Acad Sci USA 97 : 7446 7451.
39. Lenardo MJ, Chan FK, Hornung F, McFarland HF, Siegel R, Wang J, Zheng L (1999) Mature T lymphocyte apoptosis. Immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17 : 221 253.
40. Mancardi GL, Sardanelli F, Parodi RC, Melani E, Capello E, Inglese M (1998) Effect of copolymer-1 on serial gadolinium enhanced MRI in relapsing remitting multiple sclerosis. Neurology 50 : 1127 1133.
41. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, Lahat N (1998) Treatment of multiple sclerosis with copolymer-1 (Copaxone): Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 92 : 113 121.
42. Milo R, Panitch H (1995) Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 61 : 185 193.
43. Munari L, Lovati R, Boiko A (2004) Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev (1) : CD004678. Review.
44. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T, Wekerle H, Hohlfeld R (2000) Multiple sclerosis: Comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from Th1 to Th2. Proc Natl Acad Sci USA 97 : 7452 7457.
45. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343 : 938 952.
46. Pender MP (1998) Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 351 : 978 981.
47. Qin Y, Zhang DQ, Prat A, Pouly S, Antel J (2000) Characterization of T cell lines derived from glatiramer acetate-treated multiple sclerosis patients. J Neuroimmunol 108 : 201 206.
48. Ramtahal J, Jacob A, Das K, Boggild M (2006) Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing-remitting multiple sclerosis. J Neurol 253 : 1160 1164.
49. Rieks M, Hoffmann V, Aktas O, Juschka M, Spitzer I, Brune N, Schimrigk S, Przuntek H, Pohlau D (2003) Induction of apoptosis of CD4 +T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate. Eur Neurol 50 : 200 206.
50. Ruggieri M, Avolio C, Scacco S, Pica C, Lia A, Zimatore GB, Papa S, Livrea P, Trojano M (2006) Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax, and Cyt-c in peripheral lymphocytes from multiple sclerosis patients. J Neurol 253 : 231 236.
51. Sela M, Teitelbaum D (2001) Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother 2 : 1149 1165.
52. Sela M (1999) The concept of specific immune treatment against autoimmune diseases. Int Rev Immunol 18 : 201 216.
53. Sharief MK, Douglas M, Noori MA, Semra YK (2002) The expression of pro- and anti-apoptosis Bcl-2 family proteins in lymphocytes from patients with multiple sclerosis. J Neuroimmunol 125 : 155 162.
54. Sharief MK, Matthews H, Noori MA (2003) Expression ratios of the Bcl-2 family proteins and disease activity in multiple sclerosis. J Neuroimmunol 134 : 158 165.
55. Stuve O, Youssef S, Weber MS, Nessler S, Von Budingen HC, Hemmer B, Prod'homme T, Sobel RA, Steinman L, Zamvil SS (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116 : 1037 1044.
56. Teitelbaum D, Arnon R, Sela M (1997) Copolymer-1: From basic research to clinical application. Cell Mol Life Sci 53 : 24 28.
57. Teitelbaum, D, Fridkis-Hareli M, arnon R, Sela M (1996) Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 64 : 209 217.
58. Teitelbaum, D, Meshorer A, Hirshfield T, Arnon R, Sela M (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1 : 242 248.
59. Teitelbaum, D, Milo R, Arnon R, Sela M (1992) Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 89 1 : 137 141.
60. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M (1974) Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 3 : 256 262.
61. Ure DR, Rodriguez M (2002) Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J 16 : 1260 1262.
62. Van Parijs L, Abbas AK (1998) Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science 280 : 243 248.
63. Vollmer T, Panitch HS, Freedman MS (2006) Short-term induction with mitoxantrone preceding treatment with glatiramer acetate offers early and pronounced effects on MRI-disease activity in patients with relapsing forms of multiple sclerosis. Mult Scler 12 (Suppl 1 S11 S12.
64. Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C (2004) Multiple sclerosis: Glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127 : 1370 1378.
65. Wolinsky JS, Narayana PA, O'connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D (2007) Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61 : 14 24.
66. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R (2002a) Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: Implications for multiple sclerosis therapy. Brain 125 : 2381 2391.
67. Ziemssen T, Kuempfel T, Klinkert W (2002b) Glatiramer acetate-specific T cell lines produce brain-derived neurotrophic factor (BDNF) after activation upon antigen challenge in vitro: A novel mechanism of action? Neurology 58 (Suppl 3 A326.
68. Ziemssen T, Neuhaus O, Hohlfeld R (2001) Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 24 : 979 990.
69. Zipp F (2000) Apoptosis in multiple sclerosis. Cell tissue Res 301 : 163 171.
70. Zipp F, Krammer PH, Weller M (1999) Immune dysregulation in multiple sclerosis: Role of the CD95/CD95 ligand system. Immunol Today 20 : 550 554.